Opinion of the Transparency Council – prednisolone
At its meeting on 10 March 2025, the Transparency Council adopted opinion No. 39/2025 on the reimbursement of medicines containing the active substance prednisolone for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. autoimmune pancreatitis in children up to 18 years of age; eosinophilic enteritis in children up to 18 years of age